Value assessment of contralateral esophagus-sparing technique in hyperfractionated radiotherapy for limited-stage small cell lung cancer
Not Applicable
Recruiting
- Conditions
- Lung cancer
- Registration Number
- ChiCTR2400088886
- Lead Sponsor
- Shanghai Pulmonary Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age 18 to 85 years old;<br>2) Small cell lung cancer confirmed by histology or cytology;<br>3) confirmed limited stage (stage I-III, according to the 8th edition of AJCC);<br>4) Must have tumor lesions (including primary tumor or involved lymph nodes) within 1 cm of the esophagus on recent CT images;<br>5) Must have adequate organs function;<br>6) Females of childbearing potential must undergo a serum pregnancy test before the start of radiotherapy, and the result is negative;<br>7) ECOG PS 0-1; expected survival period = 12 weeks;<br>8) The subjects voluntarily joined the study and signed the informed consent form. They had good compliance and cooperated with the follow-up.
Exclusion Criteria
- With a history of tumor that has received thoracic radiotherapy in the past;<br>2) Tumors suspected or known to invade the esophagus;<br>3) Previously diagnosed with reflux esophagitis and not completely relieved;<br>4) Complicated with other diseases such as cardiovascular, urinary, digestive, hematopoietic, endocrine and metabolic systems, etc., with serious complications, liver and kidney insufficiency, and mental illness;<br>5) Patients who are pregnant or lactating women;<br>6) Patients who do not follow the doctor's advice, could not judge the curative effect or with incomplete clinical data which would affect the judgment of curative effect;<br>7) Patients with poor complications or unable to cooperate as judged by the doctor;<br>8) Researchers consider as not appropriate to participate in;<br>9) Patients refused to sign the informed consent form after a specific explanation;<br>10) With a history of allergic reactions to the chemotherapy drugs used.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severe esophagitis incidence;
- Secondary Outcome Measures
Name Time Method Objective Response Rate;Disease Control Rate;Overall survival;